WO2025110175A1 - 真珠腫治療薬 - Google Patents

真珠腫治療薬 Download PDF

Info

Publication number
WO2025110175A1
WO2025110175A1 PCT/JP2024/041108 JP2024041108W WO2025110175A1 WO 2025110175 A1 WO2025110175 A1 WO 2025110175A1 JP 2024041108 W JP2024041108 W JP 2024041108W WO 2025110175 A1 WO2025110175 A1 WO 2025110175A1
Authority
WO
WIPO (PCT)
Prior art keywords
cholesteatoma
group
carbon atoms
menin
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2024/041108
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
山本 智美 福田
直太郎 穐山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jikei University School of Medicine
Original Assignee
Jikei University School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jikei University School of Medicine filed Critical Jikei University School of Medicine
Priority to JP2025559241A priority Critical patent/JPWO2025110175A1/ja
Publication of WO2025110175A1 publication Critical patent/WO2025110175A1/ja
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a drug for treating cholesteatoma that contains a compound having a specific structure.
  • Middle ear cholesteatoma is considered to be a type of chronic otitis media, but its tissue is composed of p63-positive tympanic membrane epithelial cells, neural crest-derived cells, and fibroblasts, and shows a unique pathology different from benign and malignant tumors.
  • This disease accounts for 25% of the causes of hearing loss, and in the United States, it is reported that there are 500,000 people with the disease, and the incidence rate is 3/100,000 children and 9.2/100,000 adults. It is a progressive, intractable disease that causes damage to the middle and inner ear and is accompanied by hearing loss and dizziness, and therapeutic intervention is essential.
  • the only treatment is surgery, but recurrence and surgical complications are problems. Therefore, there is a need for a treatment that has a high inhibitory effect on cholesteatoma, that is, a treatment that has a fast therapeutic action rate and exerts its therapeutic effect at a low concentration.
  • Non-Patent Document 1 The present inventors have previously conducted research into the relationship between cholesteatoma and the post-genetic gene expression mechanism known as epigenetics, as a pathology for middle ear cholesteatoma, and reported that inhibition of histone H3K4 methylation in the promoter region has an inhibitory effect on cholesteatoma (Non-Patent Document 1). They also demonstrated that in addition to regulating the binding protein in the promoter region, regulating the binding protein in the enhancer region is important for the complete cure of cholesteatoma (Non-Patent Document 2).
  • Menin is a protein encoded by the multiple endocrine neoplasia (MEN) gene, which forms a complex with MLL (mixed-lineage leukemia), a histone H3K4 methyltransferase, promoting gene expression and interacting with numerous transcription factors (Non-Patent Document 3).
  • MLL a histone H3K4 methyltransferase
  • MLL is a member of the MLL1-MLL5 family, which forms an MLL histone methyltransferase complex with menin and catalyzes the methylation of histone H3K4 in promoter regions
  • Menin has been reported to interact with transcription factors JunD, Myc family, and FOX family that bind to enhancer regions (Non-Patent Document 3).
  • Non-covalent menin-MLL binding inhibitors are known to reversibly inhibit the binding of menin to the MLL protein complex in the promoter region.
  • covalent menin inhibitors are known to form a covalent bond with the cysteine Cys329 residue on menin and have the effect of irreversibly inhibiting the binding of the promoter region to the MLL protein complex, and are known to be usable in the treatment of cancer, etc.
  • Patent Document 1 the present inventors revealed the cholesteatoma-inhibiting effect of using a non-covalent menin-MLL binding inhibitor, but the cholesteatoma-inhibiting effect when a covalent menin inhibitor is used was unknown.
  • Yamamoto-fukuda T et al Int J Pediatr Otorhinolaryngol., 2021;140:110545 Yamamoto-fukuda T et al, J Assoc Res Otolaryngol., 2021;22:405-424 Matkar S et al, Trends Biochem Sci., 2013;38:394-402 Schuettengruber et al, Cell, 2007;128:735-745 Yamamoto-Fukuda T et al, J Assoc Res Otolaryngol., 2018;19:223-241 Yamamoto-Fukuda T et al, Sci Rep., 2023;13:4532 Yamamoto-Fukuda T et al, Eur Arch Otorhinolaryngol., 2015;272:2689-2696
  • the objective of the present invention is to provide a medicine that is effective in treating cholesteatoma.
  • the present inventors conducted a search for compounds that could be used as a fundamental treatment for cholesteatoma. As a result, they found that compounds that act as covalent menin inhibitors are effective in treating cholesteatoma, and in particular, they found that among these compounds, compounds with a specific structure are particularly effective in treating cholesteatoma, thus completing the present invention.
  • Formula I or a pharma- ceutical acceptable salt thereof,
  • R 1 is a group selected from the group consisting of H, an alkyl group having 1 to 3 carbon atoms, a halo group, a haloalkyl group having 1 to 3 carbon atoms, and CN
  • R 2a to R 2d and R 3a to R 3c are each independently a group selected from the group consisting of H, an alkyl group having 1 to 3 carbon atoms, a halo group, a haloalkyl group having 1 to 3 carbon atoms, OR, and CN, where R is H or an alkyl group having 1 to 3 carbon atoms
  • R 4a to R 4b each independently represent H or an alkyl group having 1 to 3 carbon atoms; is unsubstituted or one or more H are independently replaced by a substituent, said substituent being an alkyl group having 1 to 3 carbon atoms
  • R 1 is a group selected from the group consisting of H, an
  • R 1 is H or an alkyl group having 1 to 3 carbon atoms
  • R 2a to R 2d and R 3a to R 3c are each independently H or an alkyl group having 1 to 3 carbon atoms
  • R 4a -R 4b are each H; is unsubstituted
  • R 6a to R 6c are each independently H or an alkyl group having 1 to 3 carbon atoms.
  • the compound is or The cell proliferation inhibitor according to [1], [5] The cell proliferation inhibitor described in any of [1] to [4], wherein the cholesteatoma contains p63-positive tympanic membrane epithelial cells.
  • a pharmaceutical composition for treating and/or preventing cholesteatoma, comprising the cell proliferation inhibitor according to any one of [1] to [5] and a pharma- ceutical acceptable carrier.
  • the present invention provides a medicine that is effective in treating cholesteatoma. While the current treatment method, surgical therapy, has problems with recurrence and postoperative complications, the present invention makes it possible to treat cholesteatoma with drug therapy, thereby avoiding the risk of complications due to surgical invasion.
  • the effect of BMF-219 on the in vitro proliferation of mouse p63-positive tympanic membrane epithelial cells is shown.
  • the vertical axis indicates the cell proliferation rate (logarithm), and the horizontal axis indicates the period of compound addition.
  • the black circle symbol indicates no compound addition, the black square symbol indicates compound addition (1.0 ⁇ M), and the black triangle symbol indicates compound addition (0.5 ⁇ M).
  • the effect of Menin-MLL inhibitor 20 (MI-20) on the in vitro proliferation of mouse p63-positive tympanic membrane epithelial cells is shown.
  • the vertical axis indicates the cell proliferation rate (logarithm), and the horizontal axis indicates the period of compound addition.
  • the black circle symbol indicates no compound addition, the black square symbol indicates compound addition (1.0 ⁇ M), and the black triangle symbol indicates compound addition (0.5 ⁇ M).
  • the effect of VTP50469 on the in vitro proliferation of mouse p63-positive tympanic membrane epithelial cells is shown.
  • the vertical axis indicates the cell proliferation rate (logarithm), and the horizontal axis indicates the period of compound addition.
  • the black circle symbol indicates no compound addition, the black square symbol indicates compound addition (1.0 ⁇ M), and the black triangle symbol indicates compound addition (0.5 ⁇ M).
  • the effect of MI-463 on the in vitro proliferation of mouse p63-positive tympanic membrane epithelial cells is shown.
  • the vertical axis indicates the cell proliferation rate (logarithm), and the horizontal axis indicates the period of compound addition.
  • the black circle symbol indicates no compound addition, the black square symbol indicates compound addition (1.0 ⁇ M), and the black triangle symbol indicates compound addition (0.5 ⁇ M).
  • the effect of MI-2 on the in vitro proliferation of mouse p63-positive tympanic membrane epithelial cells is shown.
  • the vertical axis indicates the cell proliferation rate (logarithm), and the horizontal axis indicates the period of compound addition.
  • the black circle symbol indicates no compound addition, the black square symbol indicates compound addition (1.0 ⁇ M), and the black triangle symbol indicates compound addition (0.5 ⁇ M).
  • This photograph shows the results of Western blot analysis of the MYC inhibitory effect of a covalent menin inhibitor (BMF-219, Menin-MLL inhibitor 20) on mouse p63-positive tympanic membrane epithelial cells. Each group had 3 cells.
  • the inhibitory effect of BMF-219 solid line: 5.0 ⁇ M, dashed line: 50 ⁇ M
  • mouse cholesteatoma is shown.
  • the inhibitory effect of VTP50469 (solid line: 5.0 ⁇ M, dashed line: 50 ⁇ M) on mouse cholesteatoma is shown.
  • the inhibitory effect of MI-463 (solid line: 5.0 ⁇ M, dashed line: 50 ⁇ M) on mouse cholesteatoma is shown.
  • the vertical axis indicates the cholesteatoma shadow area ratio with the area before administration (Pre) set at 100, and the horizontal axis indicates the dates of micro-CT imaging before administration (Pre) and after administration (Post: 7 days after administration).
  • the inhibitory effect of MI-2 (solid line: 5.0 ⁇ M, dashed line: 50 ⁇ M) on mouse cholesteatoma is shown.
  • the vertical axis indicates the cholesteatoma shadow area ratio with the value before administration (Pre) set at 100, and the horizontal axis indicates the dates of micro-CT imaging before administration (Pre) and after administration (Post: 7 days after administration).
  • Pre the value before administration
  • Pre the horizontal axis indicates the dates of micro-CT imaging before administration (Pre) and after administration (Post: 7 days after administration).
  • Pre the value before administration
  • Post the dates of micro-CT imaging before administration
  • Post 7 days after administration
  • One embodiment of the present invention comprises: Formula I: or a pharma- ceutically acceptable salt thereof.
  • a substituent is unsubstituted or one or more H are independently substituted by a substituent, the substituent being an alkyl group having 1 to 3 carbon atoms, preferably unsubstituted.
  • the "one or more” is not particularly limited, and may be, for example, 1, 1 to 2, or 1 to 3.
  • the alkyl group having 1 to 3 carbon atoms is not particularly limited, and may be, for example, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a cyclopropyl group.
  • R 1 is a group selected from the group consisting of H, an alkyl group having 1 to 3 carbon atoms, a halo group, a haloalkyl group having 1 to 3 carbon atoms, and CN, preferably H or an alkyl group having 1 to 3 carbon atoms, more preferably H.
  • the alkyl group having 1 to 3 carbon atoms is not particularly limited, but may be, for example, a methyl group, an ethyl group, a n-propyl group, an isopropyl group, or a cyclopropyl group.
  • the halogen constituting the halo group is not particularly limited, but may be, for example, bromine, chlorine, fluorine, or iodine.
  • the haloalkyl group having 1 to 3 carbon atoms is a group in which at least one H contained in the above alkyl group is replaced with a halogen, and is not particularly limited, but may be, for example, a bromomethyl group, a chloromethyl group, a fluoromethyl group, or an iodomethyl group.
  • R 2a to R 2d and R 3a to R 3c are each independently a group selected from the group consisting of H, an alkyl group having 1 to 3 carbon atoms, a halo group, a haloalkyl group having 1 to 3 carbon atoms, OR, and CN, and R is H or an alkyl group having 1 to 3 carbon atoms, preferably each independently H or an alkyl group having 1 to 3 carbon atoms, more preferably each H.
  • the alkyl group having 1 to 3 carbon atoms is not particularly limited, but may be, for example, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a cyclopropyl group.
  • the halogen constituting the halo group is not particularly limited, but may be, for example, bromine, chlorine, fluorine, or iodine.
  • the haloalkyl group having 1 to 3 carbon atoms is a group in which at least one H contained in the alkyl group is substituted with a halogen, and may be, for example, a bromomethyl group, a chloromethyl group, a fluoromethyl group, or an iodomethyl group.
  • OR is not particularly limited, but may be, for example, a hydroxyl group, a methoxy group, an ethoxy group, or a propoxy group.
  • R 4a to R 4b each independently represent H or an alkyl group having 1 to 3 carbon atoms
  • the "one or more" is not particularly limited, and may be, for example, 1, 1 to 2, or 1 to 3.
  • the alkyl group having 1 to 3 carbon atoms is not particularly limited, and may be, for example, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a cyclopropyl group.
  • the alkyl group having 1 to 3 carbon atoms is not particularly limited, and may be, for example, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or a cyclopropyl group.
  • the halogen constituting the halo group is not particularly limited, and may be, for example, bromine, chlorine, fluorine, or iodine.
  • the haloalkyl group having 1 to 3 carbon atoms is a group in which at least one H contained in the above-mentioned alkyl group is substituted with a halogen, and may be, for example, a bromomethyl group, a chloromethyl group, a fluoromethyl group, or an iodomethyl group, without being particularly limited thereto.
  • the compound represented by formula I is preferably BMF-219 or Menin-MLL inhibitor 20 (MI-20).
  • BMF-219 is a compound represented by the following formula:
  • Menin-MLL inhibitor 20 is a compound represented by the following formula.
  • the compound of the present invention is a covalent menin inhibitor having an irreversible menin-MLL inhibitory effect and/or an irreversible MYC inhibitory effect by covalently binding to menin, preferably a covalent menin inhibitor having both an irreversible menin-MLL inhibitory effect and an irreversible MYC inhibitory effect by covalently binding to menin.
  • covalent menin inhibitors include BMF-219 and Menin-MLL inhibitor 20.
  • the menin-MLL inhibitory effect is, for example, the effect of inhibiting the binding of the promoter region with the MLL protein complex, thereby inhibiting the methylation of histone H3K4 and suppressing the expression of disease-related genes.
  • the MYC inhibitory effect is, for example, the effect of inhibiting the binding of transcription factors such as MYC that bind to enhancer regions with menin.
  • menin-MLL inhibitors for example, VTP50469, MI-463, MI-2
  • Covalent menin inhibitors having irreversible menin-MLL inhibitory activity and/or irreversible MYC inhibitory activity are expected to provide stronger inhibitory effects than menin-MLL inhibitors having reversible inhibitory activity.
  • the menin-MLL inhibitory effect can be measured by known methods. For example, but not limited to, the amount of inhibition of histone H3K4 methylation can be measured based on immunohistochemical staining or immunoblotting, and the degree of expression suppression can be measured by measuring the expression level of a target disease-related gene by PCR, and the menin-MLL inhibitory effect can be evaluated based on the results of these measurements.
  • the menin-MLL inhibitory effect may be, for example, one in which the amount of methylation of histone H3K4 or the amount of expression of a disease-related gene of interest is reduced when the compound of the present invention is added, compared to when the compound of the present invention is not added.
  • the degree of the reduction when the degree of the reduction can be quantified, it may be, for example, a reduction of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more.
  • the amount of methylation of histone H3K4 or the amount of expression of a disease-related gene of interest is reduced when the compound of the present invention is added, compared to when a control compound is added.
  • the degree of the reduction when the degree of the reduction can be quantified, it may be, for example, a reduction of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more.
  • the MYC inhibitory effect can be measured by a known method.
  • the expression level of cyclin D1 (CCND1), a downstream gene of MYC can be measured, but is not limited thereto.
  • the expression level of CCND1 can be measured by, for example, immunohistochemical staining or immunoblotting, or by PCR, or the like, to measure the protein expression level. Based on the results of these measurements, the MYC inhibitory effect can be evaluated.
  • the MYC inhibitory effect may be, for example, a decrease in the expression level of cyclin D1 (CCND1), a downstream gene of MYC, when the compound of the present invention is added, compared to when the compound of the present invention is not added.
  • the degree of the decrease when the degree of the decrease can be quantified, it may be, for example, a decrease of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more.
  • the expression level of cyclin D1 (CCND1), a downstream gene of MYC, when the compound of the present invention is added may be, for example, a decrease of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more.
  • the degree of the decrease when the degree of the decrease can be quantified, it may be, for example, a decrease of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more.
  • cholesteatoma preferably contains cells expressing p63, which is known as a marker for epithelial stem cells and/or their precursor cells in middle ear cholesteatoma tissue, and more preferably contains p63-positive tympanic membrane epithelial cells.
  • Inhibition of cell proliferation may be, for example, a decrease in the cell proliferation rate or cell number when the compound of the present invention is added compared to when the compound of the present invention is not added.
  • the degree of decrease can be quantified, it may be, for example, a decrease of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more.
  • it may be, for example, a decrease in the cell proliferation rate or cell number when the compound of the present invention is added compared to when a control compound is added.
  • the degree of decrease can be quantified, it may be, for example, a decrease of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more.
  • Pharmaceutically acceptable salts include salts of alkali metals such as sodium and potassium; magnesium salts; salts of alkaline earth metals such as calcium; salts of hydrohalic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid, and hydroiodic acid; salts of inorganic acids such as sulfuric acid, nitric acid, phosphoric acid, perchloric acid, and carbonic acid; salts of organic carboxylic acids such as formic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, hydroxyacetic acid, propionic acid, lactic acid, citric acid, tartaric acid, oxalic acid, benzoic acid, mandelic acid, butyric acid, fumaric acid, succinic acid, maleic acid, and malic acid; salts of acidic amino acids such as aspartic acid and glutamic acid; salts of basic amino acids such as arginine and lysine; ammonium salts; salts of ali
  • the compounds of this embodiment may be used either in vivo or in vitro.
  • the compound of this embodiment may be a commercially available compound, or may be a compound prepared by a method known to those skilled in the art.
  • the content of the compound represented by formula I or a pharma- ceutical acceptable salt thereof, which is the active ingredient, the dosage form, the administration site, the target disease, etc. may be described in the ⁇ Pharmaceutical composition for treating cholesteatoma> section below.
  • Another aspect of the present invention is the use of a compound of formula I or a pharma- ceutically acceptable salt thereof in the manufacture of a cytostatic agent for cholesteatoma. Another aspect of the present invention is the use of a compound of formula I or a pharma- ceutically acceptable salt thereof for the inhibition of cell proliferation in cholesteatoma. Another aspect of the invention is a compound of formula I or a pharma- ceutically acceptable salt thereof for use in the inhibition of cell proliferation for cholesteatoma. Another aspect of the present invention is a method for inhibiting cell proliferation in cholesteatoma, comprising administering to a subject in need thereof a compound represented by formula I or a pharma- ceutically acceptable salt thereof.
  • ⁇ Pharmaceutical composition for treating cholesteatoma> Another embodiment of the present invention is a pharmaceutical composition for treating and/or preventing cholesteatoma, comprising the above-mentioned cytostatic agent and a pharma- ceutically acceptable carrier.
  • Cholesteatoma is histopathologically an epidermoid cyst, and is found not only in the head and neck region, including middle ear cholesteatoma and external auditory canal cholesteatoma, but also in the whole body, such as inside the skull and on the body surface.
  • the type and site of cholesteatoma that the pharmaceutical composition of the present embodiment targets for treatment and/or prevention are not particularly limited, and may be, for example, cholesteatoma occurring in the head and neck region, such as middle ear cholesteatoma or external auditory canal cholesteatoma, or cholesteatoma occurring outside the head and neck region, such as the entire body surface tissue.
  • Cholesteatoma occurring in the head and neck region such as middle ear cholesteatoma or external auditory canal cholesteatoma, is preferred, and middle ear cholesteatoma is more preferred.
  • the degree of progression of cholesteatoma is not particularly limited. Either congenital cholesteatoma or acquired cholesteatoma may be treated, and either primary cholesteatoma or recurrent cholesteatoma may be treated.
  • the prevention may be prevention of initial cholesteatoma or prevention of recurrent cholesteatoma.
  • the therapeutic effect for example, when it is confirmed that the growth of cholesteatoma is inhibited, the number of cells constituting cholesteatoma is reduced, the size of cholesteatoma is reduced, etc. as a result of treatment with the pharmaceutical composition for treating cholesteatoma, compared with a subject before treatment with the pharmaceutical composition for treating cholesteatoma or compared with a control that was not treated with the pharmaceutical composition for treating cholesteatoma, the therapeutic effect can be determined.
  • the analysis method is not particularly limited, and can be performed by a method known to those skilled in the art.
  • the therapeutic effect can be predicted cell biologically, for example, by comparing a specimen after treatment with the pharmaceutical composition for treating cholesteatoma with a specimen before treatment with the pharmaceutical composition for treating cholesteatoma, the therapeutic effect of a therapeutic drug in vivo can be predicted.
  • the cell biological analysis is not particularly limited, but examples thereof include cell proliferation assay, Western blotting, etc., and can be performed by methods known to those skilled in the art.
  • the preventive effect for example, when a subject at high risk of developing cholesteatoma is treated with a pharmaceutical composition for treating cholesteatoma, the preventive effect can be judged to have been achieved by the fact that cholesteatoma does not develop for a certain period of time, or that cholesteatoma growth is suppressed compared to a subject at high risk of developing cholesteatoma who is not treated with a pharmaceutical composition for treating cholesteatoma.
  • the analysis method is not particularly limited, and can be performed by a method known to those skilled in the art.
  • the content of the compound represented by formula I or a pharma- ceutical acceptable salt thereof, which is the active ingredient in the pharmaceutical composition for treating cholesteatoma is not particularly limited as long as it is an amount effective for treating and/or preventing cholesteatoma. Although it generally varies depending on the dosage form, the content of the active ingredient in the pharmaceutical composition for treating cholesteatoma can be set, for example, within the range of about 0.01% by mass to about 99.9% by mass.
  • the amount of the active ingredient relative to the total amount of the pharmaceutical composition may be 1ng/mL to 1mg/mL, 1ng/mL to 100 ⁇ g/mL, 1ng/mL to 10 ⁇ g/mL, 1ng/mL to 1000ng/mL, 1ng/mL to 100ng/mL, 1ng/mL to 10ng/mL, or, for example, 1ng/mg to 1mg/mg, 1ng/mg to 100 ⁇ g/mg, 1ng/mg to 10 ⁇ g/mg, 1ng/mg to 1000ng/mg, 1ng/mg to 100ng/mg, 1ng/mg to 10ng/mg.
  • the pharmaceutical composition for treating cholesteatoma may be formulated in any dosage form.
  • parenteral dosage forms such as topical preparations, ointments, creams, ear drops, liquids, suspensions, and injections
  • oral dosage forms such as tablets, capsules, powders, and granules.
  • the mode of administration is not particularly limited, but in the case of parenteral dosage forms, examples include local administration to the affected area of the ear or the surrounding tissue, or administration to the entire body surface tissue affected by cholesteatoma or the surrounding tissue.
  • Examples of pharma- ceutically acceptable carriers include, in addition to commonly used excipients, binders, disintegrants, and lubricants, various carriers, stabilizers, surfactants, plasticizers, solubilizers, reducing agents, buffers, sweeteners, bases, adsorbents, flavorings, suspending agents, antioxidants, glossing agents, coating agents, shells, wetting agents, wetting regulators, fillers, antifoaming agents, refreshing agents, colorants, flavoring agents, flavorings, sugar coating agents, isotonic agents, softeners, emulsifiers, thickening agents, foaming agents, pH adjusters, diluents, dispersants, disintegration aids, disintegration extenders, fragrances, moisture-proofing agents, preservatives, preservatives, solubilizers, solubilization aids, solvents, fluidizing agents, antistatic agents, bulking agents, moisturizing agents, and wetting agents.
  • the pharmaceutical composition of this embodiment may contain other active ingredients as desired.
  • the subjects for administration are mammals that have developed cholesteatoma, such as humans, mice, dogs, and cats, with humans being preferred.
  • the dosage, frequency, and duration of administration of the pharmaceutical composition for treating cholesteatoma are not particularly limited as long as the compound represented by formula I or a pharma- ceutical acceptable salt thereof, which is the active ingredient, is in an amount effective for treating and/or preventing cholesteatoma, and can be adjusted appropriately according to the age, sex, weight, symptoms, therapeutic effect, area of the treatment site, dosage form, mode of administration, and the like of the subject.
  • the dosage in the case of a human adult (body weight 60 kg), can be set within the range of about 0.001 mg to about 5000 mg per day.
  • the dosage can be about 0.01 mg to about 1000 mg.
  • the pharmaceutical composition in the above dosage can be administered once per day, or in multiple divided doses per day.
  • the administration period can be, for example, one day or more and one year or less, or can be continued for a longer period.
  • Another aspect of the invention is the use of a compound of formula I, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating and/or preventing cholesteatoma.
  • Another aspect of the invention is the use of a compound of formula I or a pharma- ceutically acceptable salt thereof for treating and/or preventing cholesteatoma.
  • Another aspect of the invention is a compound of formula I or a pharma- ceutically acceptable salt thereof for use in the treatment and/or prevention of cholesteatoma.
  • Another aspect of the invention is a method of treating cholesteatoma, comprising administering to a subject having cholesteatoma a compound of formula I, or a pharma- ceutically acceptable salt thereof.
  • Example 1 Cell proliferation inhibition experiment The cell proliferation was investigated using p63-positive tympanic membrane epithelial cells, which have been reported to proliferate in cholesteatoma (Non-Patent Document 5).
  • CnT-PR basal media Cellntec, Bern, Switzerland
  • p63-positive tympanic membrane epithelial cells (passage 12) established from tympanic membrane tissue of mice with a C57BL/6 background (Jackson Laboratories, Bar Harbor, ME; Charles River Laboratories, Wilmington, MA) were used (Non-Patent Document 6).
  • Each compound listed in Table 1 was diluted with dimethyl sulfoxide (#472301, SIGMA-ALDORICH) and then further diluted with 1xD-PBS (#14249-24, Nacalai Tesque) (prepared from 10 mM or 50 mM to 500 ⁇ M or 250 ⁇ M). The compound was stored at -30°C until use, and thawed when used.
  • Cells were prepared in CnT-PR culture medium at 40,000 cells/mL and seeded (500 ⁇ L/well) into a 12-well tissue culture plate (#3815-012, IWAKI). After 24 hours, cell attachment was confirmed and then 1 ⁇ L/well of each compound (final concentration 1.0 ⁇ M or 0.5 ⁇ M) or PBS was added (day 0). The cells were then cultured for an additional 1, 3 or 5 days. One day after compound addition (day 1), three days after compound addition (day 3), and five days after compound addition (day 5), 250 ⁇ L/well of 0.25% trypsin/EDTA (#25200-072, Gibco) was added to each well and incubated at 37°C for 10 minutes.
  • trypsin/EDTA #25200-072, Gibco
  • the cell proliferation inhibitory effect of the covalent menin inhibitors (BMF-219 and Menin-MLL inhibitor 20) was observed at a concentration of 0.5 ⁇ M or higher on the first day after administration, and the cell proliferation inhibitory effect was shown to be concentration- and duration-dependent (Figs. 1-2). Furthermore, the cell proliferation inhibitory effect of the covalent menin inhibitors (BMF-219 and Menin-MLL inhibitor 20) was more effective than that of menin-MLL inhibitors (VTP50469, MI-463, MI-2) (Figs.
  • Non-Patent Document 1 that only have a reversible menin-MLL inhibitory effect similar to that of the menin-MLL inhibitor (MI-503) whose inhibitory effect on middle ear cholesteatoma has been reported in a previous paper (Non-Patent Document 1).
  • the cells were washed with PBS solution, dissolved in 75 ⁇ L of 4°C lysis solution [1 ⁇ Laemmli buffer (Bio-Rad, Hercules, CA), 2-mercaptoethanol (Wako), protein/phosphatase inhibitor cocktail (Cell Signaling Technology, Danvers, MA)], and treated at 95°C for 5 minutes, and 10 ⁇ L of each was electrophoresed on a 4-12% SDS-polyacrylamide gel (Thermo Fisher Scientific, Dreiech, Germany).
  • the proteins in the gel were transferred to a PVDF membrane (Millipore, Bedford, MA) using an electric transfer device i-blot (Invitrogen), and the membrane was immersed in 5% skim milk/0.1% Tween 20 in tris buffered saline (TBST) solution for 1 hour at room temperature with gentle stirring to block nonspecific binding.
  • the transfer PVDF membrane was immersed in primary antibodies, anti-CCND1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, mouse, sc-8396) and anti- ⁇ -actin antibody (Cell Signaling Technology, Danvers, MA, rabbit, #4970), diluted with 2.5% skim milk/0.1% TBST solution, and reacted overnight at 4°C with gentle stirring.
  • the transfer PVDF membrane was immersed in peroxidase-polymerized anti-mouse IgG antibody dilution or peroxidase-polymerized anti-rabbit IgG antibody dilution for 1 hour. After washing three times for 5 minutes with 0.1% TBST solution, the transfer PVDF membrane was immersed in ECL (GE Healthcare Biosciences, Pittsburg, PA) detection solution, and luminescence was detected using a LAS 4000 Chemiluminescence Imager (GE Healthcare). The results are shown in Figure 6.
  • covalent menin inhibitors BMF-219, Menin-MLL inhibitor 20
  • concentrations of 1.0 ⁇ M and 0.5 ⁇ M and culturing for one day the protein expression of cyclin D1 (CCND1), a downstream gene of MYC, decreased in a concentration-dependent manner.
  • ⁇ -actin used as an internal standard, showed almost equal protein amounts in all samples.
  • covalent menin inhibitors BMF-219, Menin-MLL inhibitor 20
  • Example 3 Evaluation of inhibition of cholesteatoma in mouse model KGF-induced middle ear cholesteatoma was created in both ears of ICR mice (male, 6 weeks old) and examined (Non-Patent Document 7).
  • Each compound listed in Table 1 was diluted with dimethyl sulfoxide (#472301, SIGMA-ALDORICH) and then further diluted with 1xD-PBS (#14249-24, Nacalai Tesque) (prepared from 10 mM or 50 mM to 5.0 ⁇ M or 50 ⁇ M). The compound was stored at -30°C until use and thawed before use.
  • KGF-induced middle ear cholesteatoma in both ears of ICR mice male, 6 weeks old was confirmed by 0° endoscope (AVS Co., Tokyo, Japan) or micro-CT (LaTheta LCT-200; Hitachi Aloka Medical Ltd., Tokyo, Japan).
  • Micro-CT images were taken before and 7 days after administration.
  • the temporal bone data were converted to bone conditions (gray scale, 400-2000) using the internal software of the micro-CT system, and images were acquired using Adobe Photoshop.
  • the covalent menin inhibitor (BMF-219) showed a suppressive effect on mouse cholesteatoma when administered continuously for a shorter period (7 days) at a lower concentration (5.0 ⁇ M) (Figure 7), compared with the inhibitory effect of a known menin-MLL inhibitor (MI-503, 50 ⁇ M) administered continuously for 14 days (Non-Patent Document 1).

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2024/041108 2023-11-21 2024-11-20 真珠腫治療薬 Pending WO2025110175A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025559241A JPWO2025110175A1 (cg-RX-API-DMAC7.html) 2023-11-21 2024-11-20

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023197105 2023-11-21
JP2023-197105 2023-11-21

Publications (1)

Publication Number Publication Date
WO2025110175A1 true WO2025110175A1 (ja) 2025-05-30

Family

ID=95826833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/041108 Pending WO2025110175A1 (ja) 2023-11-21 2024-11-20 真珠腫治療薬

Country Status (2)

Country Link
JP (1) JPWO2025110175A1 (cg-RX-API-DMAC7.html)
WO (1) WO2025110175A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516057A (ja) * 2018-12-31 2022-02-24 バイオメア フュージョン,エルエルシー メニン-mll相互作用の不可逆的阻害剤
WO2023022912A1 (en) * 2021-08-20 2023-02-23 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516057A (ja) * 2018-12-31 2022-02-24 バイオメア フュージョン,エルエルシー メニン-mll相互作用の不可逆的阻害剤
WO2023022912A1 (en) * 2021-08-20 2023-02-23 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Menin-MLL inhibitor 20", MEDCHEMEXPRESS (ACCESSED VIA THE WAYBACK MACHINE), 7 December 2021 (2021-12-07), XP093318484, Retrieved from the Internet <URL:https://web.archive.org/web/20211207155600/https://www.medchemexpress.com/menin-mll-inhibitor-20.html> *
BORKIN, DMITRY ET AL.: "Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction", J. MED. CHEM., vol. 61, 2018, pages 4832 - 4850, XP055594168, DOI: 10.1021/acs.jmedchem.8b00071 *
XU, SHILIN ET AL.: "Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction", ANGEW. CHEM. INT. ED., vol. 57, 2018, pages 1601 - 1605, XP055644297, DOI: 10.1002/anie.201711828 *
XU, SHILIN ET AL.: "Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity", J. MED. CHEM., vol. 63, 2020, pages 4997 - 5010, XP055749739, DOI: 10.1021/acs.jmedchem.0c00547 *
YAMAMOTO-FUKUDA TOMOMI; AKIYAMA NAOTARO; TATSUMI NORIFUMI; OKABE MASATAKA; KOJIMA HIROMI: "Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo", INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY., ELSEVIER, AMSTERDAM,, NL, vol. 140, 3 December 2020 (2020-12-03), NL , XP086420113, ISSN: 0165-5876, DOI: 10.1016/j.ijporl.2020.110545 *

Also Published As

Publication number Publication date
JPWO2025110175A1 (cg-RX-API-DMAC7.html) 2025-05-30

Similar Documents

Publication Publication Date Title
Tang et al. Piceatannol inhibits the IL-1β-induced inflammatory response in human osteoarthritic chondrocytes and ameliorates osteoarthritis in mice by activating Nrf2
US11247970B2 (en) Selective inhibition of gluconeogenic activity
CA3112695C (en) Composition for treating fibrotic diseases, comprising benzhydryl thioacetamide compound as active ingredient
US11278549B2 (en) Method of treating obesity
JP6473938B2 (ja) 抗線維化化合物、その方法および使用
JPWO2020095971A1 (ja) 老化細胞を除去する方法、および老化細胞の調製方法
KR20070102492A (ko) 혈관형성 억제 약학적 조성물의 제조를 위한디케토디티오피페라진 항생제의 용도
JP2009541214A (ja) マクロファージ遊走阻止因子アンタゴニスト及びそれを用いた方法
US9937173B2 (en) Method of treating obesity
US8771682B2 (en) Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
WO2018043476A1 (ja) 筋萎縮性側索硬化症治療剤及び治療用組成物
JP6918839B2 (ja) 概日時計の乱れに関連するマイクロバイオームの調節異常を処置するための方法及び医薬組成物
JP7682541B2 (ja) 新規化合物およびこれを有効成分として含む呼吸器疾患の予防または治療用組成物
EP3517108B1 (en) Application of src homology region 2-containing protein tyrosine phosphatase-1 agonist for improving fibrosis
WO2024225368A1 (ja) アデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤、乾癬治療剤並びにアデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤及び乾癬治療剤の製造のための化合物の使用
GB2597731A (en) Preterm labour
WO2017211318A1 (zh) 一种具有抗肿瘤作用的topk抑制剂
KR102322102B1 (ko) 염증성 질환의 예방, 개선 또는 치료용 조성물
JP2025129655A (ja) インフラマソーム阻害剤
CA3255975A1 (en) Flavonoid compounds, as well as methods and materials for using flavonoid compounds to treat fibrotic conditions
JP2021020875A (ja) がん幹細胞の自己複製阻害剤及びstat3のリン酸化阻害剤
TW201943716A (zh) 吳茱萸次鹼類似物及其應用
HK1134997A (en) Macrophage migration inhibitory factor antagonists and methods of using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24894166

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025559241

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025559241

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE